264 related articles for article (PubMed ID: 28757166)
41. Neuropsychiatric conditions among patients with dyskeratosis congenita: a link with telomere biology?
Rackley S; Pao M; Seratti GF; Giri N; Rasimas JJ; Alter BP; Savage SA
Psychosomatics; 2012; 53(3):230-5. PubMed ID: 22458992
[TBL] [Abstract][Full Text] [Related]
42. The role of telomere biology in bone marrow failure and other disorders.
Savage SA; Alter BP
Mech Ageing Dev; 2008; 129(1-2):35-47. PubMed ID: 18160098
[TBL] [Abstract][Full Text] [Related]
43. Impaired Telomere Maintenance and Decreased Canonical WNT Signaling but Normal Ribosome Biogenesis in Induced Pluripotent Stem Cells from X-Linked Dyskeratosis Congenita Patients.
Gu BW; Apicella M; Mills J; Fan JM; Reeves DA; French D; Podsakoff GM; Bessler M; Mason PJ
PLoS One; 2015; 10(5):e0127414. PubMed ID: 25992652
[TBL] [Abstract][Full Text] [Related]
44. Telomere maintenance and human bone marrow failure.
Calado RT; Young NS
Blood; 2008 May; 111(9):4446-55. PubMed ID: 18239083
[TBL] [Abstract][Full Text] [Related]
45. Dyskeratosis congenita: telomerase, telomeres and anticipation.
Marrone A; Walne A; Dokal I
Curr Opin Genet Dev; 2005 Jun; 15(3):249-57. PubMed ID: 15917199
[TBL] [Abstract][Full Text] [Related]
46. Chemical inhibition of PAPD5/7 rescues telomerase function and hematopoiesis in dyskeratosis congenita.
Shukla S; Jeong HC; Sturgeon CM; Parker R; Batista LFZ
Blood Adv; 2020 Jun; 4(12):2717-2722. PubMed ID: 32559291
[TBL] [Abstract][Full Text] [Related]
47. TINF2 mutations result in very short telomeres: analysis of a large cohort of patients with dyskeratosis congenita and related bone marrow failure syndromes.
Walne AJ; Vulliamy T; Beswick R; Kirwan M; Dokal I
Blood; 2008 Nov; 112(9):3594-600. PubMed ID: 18669893
[TBL] [Abstract][Full Text] [Related]
48. Clonal hematopoiesis in patients with dyskeratosis congenita.
Perdigones N; Perin JC; Schiano I; Nicholas P; Biegel JA; Mason PJ; Babushok DV; Bessler M
Am J Hematol; 2016 Dec; 91(12):1227-1233. PubMed ID: 27622320
[TBL] [Abstract][Full Text] [Related]
49. Late Effects Screening Guidelines after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects After Pediatric HCT.
Dietz AC; Savage SA; Vlachos A; Mehta PA; Bresters D; Tolar J; Bonfim C; Dalle JH; de la Fuente J; Skinner R; Boulad F; Duncan CN; Baker KS; Pulsipher MA; Lipton JM; Wagner JE; Alter BP
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1422-1428. PubMed ID: 28533057
[TBL] [Abstract][Full Text] [Related]
50. Dyskeratosis congenita as a disorder of telomere maintenance.
Nelson ND; Bertuch AA
Mutat Res; 2012 Feb; 730(1-2):43-51. PubMed ID: 21745483
[TBL] [Abstract][Full Text] [Related]
51. Dyskeratosis congenita and the DNA damage response.
Kirwan M; Beswick R; Walne AJ; Hossain U; Casimir C; Vulliamy T; Dokal I
Br J Haematol; 2011 Jun; 153(5):634-43. PubMed ID: 21477209
[TBL] [Abstract][Full Text] [Related]
52. Paracrine Interaction of Cancer Stem Cell Populations Is Regulated by the Senescence-Associated Secretory Phenotype (SASP).
Lagunas AM; Francis M; Maniar NB; Nikolova G; Wu J; Crowe DL
Mol Cancer Res; 2019 Jul; 17(7):1480-1492. PubMed ID: 31043491
[TBL] [Abstract][Full Text] [Related]
53. Pot1b deletion and telomerase haploinsufficiency in mice initiate an ATR-dependent DNA damage response and elicit phenotypes resembling dyskeratosis congenita.
He H; Wang Y; Guo X; Ramchandani S; Ma J; Shen MF; Garcia DA; Deng Y; Multani AS; You MJ; Chang S
Mol Cell Biol; 2009 Jan; 29(1):229-40. PubMed ID: 18936156
[TBL] [Abstract][Full Text] [Related]
54. Dyskeratosis congenita.
Bessler M; Wilson DB; Mason PJ
FEBS Lett; 2010 Sep; 584(17):3831-8. PubMed ID: 20493861
[TBL] [Abstract][Full Text] [Related]
55. Molecular mechanisms of telomere biology disorders.
Grill S; Nandakumar J
J Biol Chem; 2021; 296():100064. PubMed ID: 33482595
[TBL] [Abstract][Full Text] [Related]
56. Comparable Effects of the Androgen Derivatives Danazol, Oxymetholone and Nandrolone on Telomerase Activity in Human Primary Hematopoietic Cells from Patients with Dyskeratosis Congenita.
Vieri M; Kirschner M; Tometten M; Abels A; Rolles B; Isfort S; Panse J; Brümmendorf TH; Beier F
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33003434
[TBL] [Abstract][Full Text] [Related]
57. Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA.
Fogarty PF; Yamaguchi H; Wiestner A; Baerlocher GM; Sloand E; Zeng WS; Read EJ; Lansdorp PM; Young NS
Lancet; 2003 Nov; 362(9396):1628-30. PubMed ID: 14630445
[TBL] [Abstract][Full Text] [Related]
58. A child with severe form of dyskeratosis congenita and TINF2 mutation of shelterin complex.
Sarper N; Zengin E; Kılıç SÇ
Pediatr Blood Cancer; 2010 Dec; 55(6):1185-6. PubMed ID: 20979174
[TBL] [Abstract][Full Text] [Related]
59. The role of telomere binding molecules for normal and abnormal hematopoiesis.
Hosokawa K; Arai F
Int J Hematol; 2018 Jun; 107(6):646-655. PubMed ID: 29550946
[TBL] [Abstract][Full Text] [Related]
60. Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita.
Alter BP; Baerlocher GM; Savage SA; Chanock SJ; Weksler BB; Willner JP; Peters JA; Giri N; Lansdorp PM
Blood; 2007 Sep; 110(5):1439-47. PubMed ID: 17468339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
